OSTIUM BIO · TECHNICAL NARRATIVE · 2026
The dose was never the problem.
The clock was.
KAIROS-1 gives a week-long GLP-1 drug back its two-minute rhythm.
01 — THE SIGNAL
Your gut writes a two-minute letter.
Eat, and the L-cells lining your lower intestine fire. They release GLP-1: a thirty-amino-acid peptide that tells the pancreas to make insulin, tells the stomach to empty slowly, and tells the brain it has had enough.
Then it is destroyed. An enzyme called DPP-4 clips two amino acids off the front and the message stops meaning anything. Half-life, about two minutes. Your body writes the letter, sends it, and burns it before you finish the meal.
The rhythm is not a flaw in the system. The rhythm is the system.
02 — THE FIX, AND ITS SHAPE
So we built a molecule that will not die.
Bolt a fatty acid chain onto the peptide. The chain grips albumin, hides the DPP-4 cut site, and rides the bloodstream for days. Half-life goes from two minutes to about one hundred and sixty-five hours.
It is a spectacular piece of chemistry and it works. What it also does is change the shape of the signal. The spike becomes a shelf. The trough never arrives.
The same message, held down like a piano key.
03 — WHAT FLAT COSTS
A signal with no trough is a signal with no off.
We followed 412 people through a year of weekly dosing. Every one of them lost weight. We were not asking whether it worked. We were asking what else the flat line changed.
through weeks 1 to 6
lean tissue, not fat
measured against baseline
Weight came off. Something else came off with it.
04 — THE MECHANISM
The receptor is not a switch.
It is a listener.
GLP-1R does not count molecules. Hold it open and the cell pulls the receptor off its own surface and recycles it. Pulse it, and the receptor stays where it is, waiting for the next one.
Our model says the cell reads the rate of change, not the total dose. Two deliveries with identical area under the curve leave two completely different cells.
Same drug. Same amount. One surface intact, one stripped.
05 — THE DEVICE
KAIROS-1
Eleven millimetres of titanium and glass, placed under the skin of the upper arm. It carries no reservoir large enough to matter on its own. It carries 340 of them.
Each reservoir is capped with a polymer membrane that opens when its electrode is charged. There is no pump and no moving part. To dose, KAIROS-1 breaks a wall.
06 — THE LOOP
Sense. Predict. Pulse.
Let it die.
The tip samples interstitial fluid every ninety seconds. A forty-kilobyte model on the die watches for the shape of a meal beginning: glucose rising with bile acid, in that order, at that rate. It does not wait for the peak. It fires six to eleven minutes ahead of it.
Then it stops. What we release has a native half-life and is meant to disappear. The trough is not a side effect of the design.
The trough is the product.
07 — RESULTS
Ninety-six people.
Twenty-six weeks.
KAIROS-1 against a weekly injectable, matched for total peptide delivered. Same drug, same amount. Only the timing changed.
We did not beat the injectable on weight. We were never trying to. We matched it, and gave back the muscle and the mornings.
All values shown as percent.
Timing is a molecule.
KAIROS-1 enters a first-in-human study in Q2 2027.